Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Trial Profile

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Blinatumomab (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Rituximab (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Thiotepa (Primary)
  • Indications Haematological malignancies; Lymphoid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Non-Hodgkin's lymphoma; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 30 Jun 2020 to 1 Jun 2020.
    • 28 Sep 2017 Planned primary completion date changed from 30 Jun 2019 to 1 Jun 2019.
    • 07 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top